ARTICLE | Company News
Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub
May 6, 2019 9:16 PM UTC
Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a psychiatric biomarker strategy to support its clinical trials.
Abide's shareholders will receive $250 million up front and are eligible for $150 million in milestones...
BCIQ Target Profiles